Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Eide

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Cancer Research|July 27, 2013
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitorsAmie S Corbin, Thomas O'Hare, Zhimin Gu, et al.
Cell Reports|March 30, 2017
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaAlyssa Carey, David K Edwards, Christopher A Eide, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasm cellsBruna Alves Fenerich, Jaqueline Cristina Fernandes, Ana Paula Nunes Rodrigues Alves, et al.
Oncotarget|June 7, 2018
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samplesDavid K Edwards V, David Tyler Sweeney, Hibery Ho, et al.
Cancer Cell|August 30, 2024
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapyChristopher A Eide, Diana Brewer, Tao Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung CancerAlexander Drilon, Romel Somwar, Jacob P Wagner, et al.
Oncotarget|January 13, 2016
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasmsPaula de Melo Campos, João A Machado-Neto, Christopher A Eide, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracyLeyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell DiseasesOlivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Cell Reports. Medicine|December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemiaMelissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Cancer Research|July 27, 2013
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitorsAmie S Corbin, Thomas O'Hare, Zhimin Gu, et al.
Cell Reports|March 30, 2017
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaAlyssa Carey, David K Edwards, Christopher A Eide, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasm cellsBruna Alves Fenerich, Jaqueline Cristina Fernandes, Ana Paula Nunes Rodrigues Alves, et al.
Oncotarget|June 7, 2018
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samplesDavid K Edwards V, David Tyler Sweeney, Hibery Ho, et al.
Cancer Cell|August 30, 2024
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapyChristopher A Eide, Diana Brewer, Tao Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung CancerAlexander Drilon, Romel Somwar, Jacob P Wagner, et al.
Oncotarget|January 13, 2016
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasmsPaula de Melo Campos, João A Machado-Neto, Christopher A Eide, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracyLeyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell DiseasesOlivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Cell Reports. Medicine|December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemiaMelissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Pageof 12